Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Thriving Under Value-Based Reimbursement with Behavioral Screening and Intervention (BSI) (1 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    As value-based reimbursement continues to expand, healthcare organization leaders increasingly appreciate the importance of behavioral health but aren’t sure what to do about it. Simply hoping that providers will recognize and treat or refer patients for behavioral health issues will no longer “cut it.” In this session, attendees will learn how to advise healthcare leaders on Behavioral Screening and Intervention, an evidence-based, cost-saving, proactive approach to identifying and addressing behavioral risks and disorders.

    Healthcare organizations across the nation are scrambling to adapt to value-based reimbursement. Most healthcare leaders know that behavioral health is important, but they aren't sure what to do about it. This is a huge opportunity for addiction treatment professionals who can offer solutions beyond conventional referral resources. Under MACRA, primary healthcare settings must choose to be reimbursed through alternative payment models (APMs) such as accountable care organizations (ACOs), or through the Merit-based Incentive Payment System (MIPS). Under bundled payment programs, Medicare will provide one lump-sum reimbursement for patients with certain conditions, regardless of actual costs. Under APMs, MIPS and bundles, the financial well-being of healthcare organizations will hinge on their success at improving health outcomes and controlling healthcare costs across large populations of patients. Behavioral health issues are key determinants of outcomes and costs. Simply hoping providers will recognize and treat or refer patients for behavioral health issues will no longer cut it. A proactive, population-wide approach is necessary. That approach is behavioral screening and intervention (BSI). All patients are systematically screened for key behavioral risks and disorders. Healthcare teams are expanded with coaches, who have the training and time to provide robust, evidence-based interventions - motivational interviewing and behavior change planning for smoking and unhealthy drinking and drug use, and collaborative care for depression. Although coaches and primary care providers can handle most issues, BSI will generate more referrals for mental health and addictive disorders. This session will cover the prevalence, health effects and economic impacts of behavioral issues. It will define and describe the process of BSI. It will cite research on the effectiveness and cost savings of components of BSI. It will describe how BSI was implemented at dozens of healthcare settings in Wisconsin and the results - high patient satisfaction, substantial improvement in behavioral outcomes, and nearly $800 two-year, net healthcare cost savings per Medicaid patient screened. It will describe how BSI can serve as the framework for primary care/behavioral health integration and the hub for chronic disease management. The participants will learn how to advise healthcare organizations on integrating BSI into a variety of general healthcare settings, enhance their credibility as systems-level behavioral health consultants, and help their organizations thrive under value-based reimbursement.

    Richard L. Brown

    MD, MPH

    Dr. Brown is a family physician and a tenured full professor in the Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin. His academic focus has been the primary care management of alcohol and drug disorders and other behavioral risk factors and conditions. He has conducted NIH-funded research, published dozens of peer reviewed articles, made numerous presentations, and conducted workshops in these realms on four continents. He served as president of the Association for Medical Education and Research in Substance Abuse (AMERSA) from 1997 to 1999 and received AMERSA's McGovern award for excellence in medical education in 2002. From 1999 to 2004, he served as the founding director of Project MAINSTREAM (www.projectmainstream.net), a federally funded program that enhanced substance abuse education for twelve health professions and improved education for over 10,000 trainees. Since 2006, he has served as Director for the Wisconsin Initiative to Promote Healthy Lifestyles (www.wiphl.com). WIPHL has helped 40 general healthcare settings provide over 110,000 screens and 25,000 interventions, garner excellent patient satisfaction, and elicit substantial declines in risky and problem drinking. Dr. Brown is owner and CEO of Wellsys, LLC (www.wellsys.co), which provides software, consulting, training and clinical support to enable healthcare settings to provide systematic, evidence-based, cost-saving screening and intervention services for the behavioral risks and disorders responsible for over 40% of deaths, most chronic disease and disability and nearly $1 trillion in costs per year.

  • Use and Interpretation of Buprenorphine Metabolite Profiles During Maintenance Treatment (1 CME)

    Contains 3 Component(s), Includes Credits

    Using urine buprenorphine and metabolite levels to provide insight into treatment compliance, adulteration and misuse of buprenorphine.

    Urine drug testing during medication-assisted treatment with buprenorphine involves not only assessment for illicit and non-prescribed substances but also involves confirmation of appropriate use of buprenorphine. While standard urine drug screens provide a glimpse into individual patient drug use patterns, the buprenorphine/metabolite levels provide insight into compliance; adding the urine creatinine (Cr) allows for standardization of levels despite fluctuations in urine concentration. Trending the total buprenorphine and metabolite profiles, and comparing the buprenorphine metabolite-Cr ratios, provides information about how the patient is taking their medication. Profiles can also be used to detect urine adulteration (e.g. urine spiked with buprenorphine) and misuse. The presence of appropriate levels of buprenorphine and metabolites, when standardized to urine Cr, are evidence of compliance over time. A compliant patient will have fairly low levels of buprenorphine and higher levels of the metabolites (norbupnor buprenorphine/Cr). Someone with intermittent buprenorphine use will have much lower metabolite levels than someone maintained on stable doses taken daily. Adding medication to the urine results in a very different profile than stable dosing with very high buprenorphine levels (Tbup/Cr >4000 ng/mg Cr), naloxone in the urine, and negligible Tnorbup/Cr levels. This indicates that the medication, the buprenorphine/naloxone, was put directly into the urine. While tests must be interpreted in the context of patient self-report and other information such as attendance, participation in group and counseling activities, and reports of progress from family, spouse, counselors and other reliable sources, the confirmation and quantification of urine buprenorphine and metabolite levels can suggest deviations and inconsistency with dosing over time. They can also be used to confirm compliant dosing. Appropriate use and interpretation can help providers anticipate and then mitigate untoward complications of therapy. This session involves didactic based presentation including a review of buprenorphine metabolism and elimination. Interpretation of drug testing results involving detection and quantification of various buprenorphine metabolite profiles is done through case-based discussion using examples from my clinical practice, in which interpretation of these levels was used to guide therapy. Specific cases involving compliant patients from induction to stabilization are compared to illicit and street use profiles. Examples of substitution and adulteration are presented. Questions will be posed to the audience using an Audience-Response-System and interactive discussion is included in order to best answer the questions and present the material. In addition to test interpretation appropriate testing frequency and use of alternative matrices (e.g. saliva/oral testing) was compliment to urine testing is covered. This material is in follow-up from a previous presentation on buprenorphine metabolite profiles in urine drug testing which was presented in abstract and poster format at the 2016 ASAM Conference in Baltimore, MD (1). Effective use of urine drug testing requires not only the right test with appropriate components but also knowledge of the pharmacologic principles of metabolism and elimination. Appropriate testing can reinforce compliance, and deter medication misuse and diversion. Testing during addiction treatment, in buprenorphine maintenance, is part of a primary prevention and disease management program.

    Timothy J. Wiegand

    MD, FACMT, FAACT, FASAM

    Tim Wiegand MD, DABAM, FACMT, FAACT was trained in internal medicine and completed fellowship training in Medical Toxicology at the University of California, San Francisco in 2006. He was the Medical Director of the Rochester Poison Center until 2010. Dr. Wiegand has been successful in developing a full time, bedside, medical toxicology consultation service and is very active in the practice of Addiction Medicine, having successfully completed his board certification recently. 

    In addition to his primary appointment as Associate Professor of Emergency Medicine at the University of Rochester School of Medicine & Dentistry in Rochester, NY, Dr. Wiegand serves as Medical Director for Huther Doyle Chemical Dependency Treatment Program in Rochester, NY and as a detoxification specialist for Syracuse Behavioral Health in Rochester, NY. 

    Dr. Wiegand serves on the New York Society of Addiction Medicine (NYSAM) Board of Directors as the Communication Committee Chair and he was recently elected to the American College of Medical Toxicology Board of Directors to begin a 3 year term in October, 2015. He currently serves as the chair of the Addiction Medicine Section for the American College of Medical Toxicology and he recently organized a very successful Addiction Medicine Academy for ACMT prior to their main Annual Scientific Meeting in Clearwater, Florida in March, 2015. Dr. Wiegand has presented for the ASAM Review Course on Pharmacology & Toxicology, MRO and drug testing principles at previous Review Course conferences.

    Martin Siegrist

    RPA-C, LAc

    Martin Siegrist RPA-C, L.Ac. attended the University of Rochester and graduated in 1984.  He received his PA credentials from the SUNY Stony Brook in 1991. Martin has been working the field of addiction for 25 years including inpatient detox, inpatient rehab as well as outpatient addiction medicine. He is currently the Assistant Medical Director of Huther Doyle, an outpatient substance use disorder treatment program in Rochester, NY.

  • Using Project ECHO to Spread Office-Based MAT: Life-Saving System Transformation (1 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    In this presentation, we will review a brief history of the separation of addiction treatment from the medical establishment. We will introduce the Harm Reduction model, and compare how that model fits with traditional treatment models as opposed to with Medication-Assisted Treatment (MAT). We will share our process of building a MAT program in a rural primary care network, including our use of the Extension of Community Healthcare Outcomes (ECHO) model to build competency in including MAT as part of comprehensive primary care.

    Opioid addiction is an increasing problem in the United States. Effective treatment options exist, but are often challenging to access, especially for patients who live in remote, rural areas. There is a long history of separation of treatment of addiction and medicine, and certainly a disconnect between primary care and treatment for opioid addiction. Included in the reasons for separation from primary care are special training and licensing requirements, and a paucity of education regarding primary care-based treatment options for patients struggling with opioid addiction. Office-based treatment with buprenorphine is an evidence-based approach to helping patients with opioid addiction avoid illicit opioid use and re-engage with a meaningful and productive life. However, effective implementation requires that health system administration, primary care physicians, and primary care staff both overcome decades of stigma and learn how to safely administer treatment, while also running an efficient and patient-centered comprehensive primary care clinic. Like many potentially effective treatments, both pharmacological (e.g., anti-depressant medications) and behavioral (e.g., time-outs for unwanted behavior from children), it is essential that the treatment be properly executed to maximize positive outcomes. Project ECHO (Extension of Community Healthcare Outcomes) started as an innovative approach to increasing access to effective treatment for hepatitis C to rural, community-based care clinics in New Mexico. The project was a success, with patients receiving care in primary care centers demonstrating outcomes that were as good as those for patients getting care from a specialist, but from a center that was much more convenient to access. It used a hub-and-spoke video conferencing model to connect community primary care clinics both with an expert team (hub) and one another (spokes). This model allowed specialty knowledge to spread from the hub to the spokes, as well as practical, primary-care focused expertise to be shared between the various primary care teams participating (spokes). Following the success of the original project, the ECHO model has spread to other states, and been used to spread other times of specialty care knowledge in an effort to exponentially increase capacity to treat, and reduce health care inequities. In this presentation, we will review a brief history of the separation of addiction treatment from the medical establishment. We will introduce the Harm Reduction model, and compare how that model fits with traditional treatment models as opposed to with Medication-Assisted Treatment (MAT). We will review data relevant to MAT, in regards to outcomes as well as risks of treatment. We will share our process of building a MAT program in a rural primary care network, as well as discussing complementary components of a comprehensive effort to reduce rates of addiction. We will share available data from the project-in-progress, and encourage audience members to engage with us in discussion, about both the process of building such a program, as well as the risks and benefits of this approach to treating opioid addiction.

    James B. Anderson

    PhD

    James B. Anderson, PhD, Licensed Psychologist, Leatherstocking Healthcare Collaborative Partnership & Bassett Healthcare Network, completed his PhD in Clinical Psychology at Western Michigan University in 2010, and a Postdoctoral Fellowship in Primary Care Integrated Behavioral Health at the University of Massachusetts Medical School in 2012.   He has been an assistant professor at the University of Massachusetts Medical School, and the co-director of Behavioral Science for the Family Medicine Residency at Hennepin County Medial Center in Minneapolis, Minnesota.  He currently serves as the New York State Medicaid Delivery System Reform Incentive Payment (DSRIP) program, and works as a clinical psychologist providing integrated prinary care behavioral health services for Bassett Healthcare Network in Upstate New York.

    Stephen A. Martin

    MD, EdM

    Stephen Martin, MD, EdM, is an Associate Professor of Family Medicine and Community Health at the University of Massachusetts Medical School.  He also serves as residency faculty at Boston University School of Medicine and is a member of the faculty at Harvard Medical School’s Center for Primary Care.  He is a graduate of Williams College, the Harvard Graduate School of Education, Harvard Medical School, and a residency in Family Medicine at Boston University.

    After four years with the National Health Service Corps in a community health center and federal prison medical center, Steve’s clinical site has been the Barre Family Health Center, a source of health care for ten rural towns.  He is on the faculty for the center’s 12 residents and co-directs the University of Massachusetts’ Rural Health Scholars Program and the UMass Project ECHO for Opioid Use Disorder.  He is founding project director of TandemHealth , a partnership between Consumer Reports and the National Physician Alliance to develop independent electronic resources for training and practicing clinicians as well as patients.  In 2013, he was named Preceptor of the Year by the Massachusetts Academy of Family Physicians.  Steve is the lead author of publications in the BMJ, JAMA, Lancet, and the American Journal of Public Health.
    He is a member of the RightCare Alliance Primary Care Council and co-founder of Care that Matters. His chief professional goal is to redress the Inverse Care Law.

    Joseph R. Sellers

    MD, FAAP, FACP

    Joseph R. Sellers MD, FAAP, FACP is a practicing Internist and Pediatrician who serves as the Eastern Region Medical Director for the Bassett Helthcare Network in Upstate New York. Dr. Sellers is the lead physician for a New York Medicaid - Delivery System Reform Incentive Program project to integrate medical assisted treatment for opioid abuse into primary care practices and to improve colaboration between primary care  medical providers and community substance abuse programs.

    Dr. Sellers is a graduate of the University of Rochester and the Georgetown University School of Medicine. He completed his residency in Internal Medicine and Pediatrics at the Albany ( NY) Medical Center. He is board certified in Internal Medicine and Pediatrics and is a Fellow of the American Academy of Pediatrics and the American College of Physicians.Dr, Sellers is an Assistant Clinical Professor of Medicine at the Columbia University College of Physicians and Surgeons. He serves as treasurer of the Medical Society of the State of New York, is a member of the Schoharie County ( NY) Board of Health, the Board of Trustees of Cobleskill Regional Hospital and the Executive Board of the  Leatherstocking Council, Boy Scouts of America.

    Daniel Mullin

    PsyD

    Daniel Mullin, PsyD is an Associate Professor at the University of Massachusetts Medical School.

  • Teamwork Training to Enhance Effectiveness and Patient Safety in Addiction Medicine (1 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    The presenters will provide an introduction to the concepts of teamwork enhancement as it may apply to care providers within the field of addiction care. Attendees may identify areas in which opportunities for improvement exist in their current or past working environment.

    Few areas in healthcare depend upon effective teamwork as much as addiction medicine. Providers from medical, nursing, social work, and administrative personnel inevitably function in teams that must provide comprehensive care to patients with multiple and diverse needs. However, care may be compromised if teams do not function successfully. Fragmentation of care and limited coordination lead to inadequate and poor quality care, patient safety concerns, low patient satisfaction and program drop-out. Constricted or limited communication lines may additionally compromise the care provided. Furthermore, operational inefficiencies increase costs, decrease employee satisfaction, leading to higher employee turn-over and burnout. Everyone loses. TeamSTEPPS represents a proven, effective tool for the development of teams in healthcare. It is designed to improve patient care through enhanced teamwork. While TeamSTEPPS was originally designed in the military over 20 years ago, it has been widely adapted for hospital-based work, it has since been applied to a number of outpatient settings, including physician office practice settings, with success. TeamSTEPPS is also known to improve team efficiencies and enhance worker satisfaction. The presenters will provide an overview of team functioning rules to help organizations and individuals recognize the opportunities to provide safer and more effective care. This 60-minute workshop is very interactive with multiple video clips and audience involvement to engage all participates in building and practicing good techniques. Those in attendance will leave this workshop with multiple, easily deployed, first "stepps" towards building enhanced competencies in functioning in teams.

    Charles W. Schauberger

    MD, MS, CPE

    Dr. Charles Schauberger is an obstetrician who practices at Gundersen Health System in La Crosse, Wisconsin. He attended University of Iowa Medical School and completed a residency in Obstetrics & Gynecology at the same location many years ago. He received a MS in Administrative Medicine from the University of Wisconsin- Madison. He has published over 40 articles in the peer review literature. He is passionate about the care of pregnant women with addictions.

    Grena Porto

    RN, MS, ARM, CPHRM

    Grena is a nationally recognized expert and leader in patient safety, risk management and quality improvement.  Grena has over 25 years’ experience in all areas of risk management, including loss prevention, risk financing and claims management. She served as regional claims manager for a large national insurer, and was also director of risk management at a large academic medical center in New York. Early in her career she served as risk management coordinator for a 10-member group captive in New York City. She also was employed as a professional liability claims analyst for a well-known third-party administrator. More recently, she operated her own healthcare risk management consulting firm for 10+ years and also served as Sr. Vice President and Client Executive for a large multinational brokerage firm.

    She is a past President of the American Society for Healthcare Risk Management (ASHRM) and has served on the Board of Directors of the National Patient Safety Foundation (NPSF). She currently serves on the Joint Commission's Patient Safety Advisory Group. 
    Grena is also a Distinguished Fellow of ASHRM and has also attained the designations of Associate in Risk Management (ARM) from the Insurance Institute of American, and Certified Professional in Healthcare Risk Management (CPHRM) from the American Hospital Association. She holds a Bachelor of Science in Nursing and Master of Science in Health Administration from the State University of New York at Stony Brook. Grena has lectured extensively both nationally and internationally, and is the author of numerous publications on risk management and patient safety.

  • Using PMP's and SBIRT to Address Physician Controlled Drug Prescribing (1 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    The prudent prescribing of controlled drugs has been a challenge for decades. Balancing prescribing for legitimate medical purpose while avoiding prescribing in high risk situations has been one of the most difficult aspects to address. This is partly due to suboptimal screening for high risk patients by prescribers prior to and during chronic controlled drug prescribing. The development of US Prescription Monitoring Programs has brought about the clinical expectation that Substance Abuse Treatment Programs (SATPs) will perform a PMP web-site search on all patients evaluated for problematic substance use.

    The prudent prescribing of controlled drugs has been a challenge for decades. Balancing prescribing for legitimate medical purpose while avoiding prescribing in high risk situations has been one of the most difficult aspects to address. This is partly due to suboptimal screening for high risk patients by prescribers prior to and during chronic controlled drug prescribing. It is also due to inadequate attention to the seriousness of the relative contraindications to long term controlled drug prescribing including current or past substance use disorder on the part of the patient. The development of US Prescription Monitoring Programs has brought about the clinical expectation that Substance Abuse Treatment Programs (SATPs) will perform a PMP web-site search on all patients evaluated for problematic substance use. This technology now provides SATPs with large amounts of information about their patient's sources of controlled drugs. What has not been common is a systematic evidence based approach to using this new data from PMP profiles. We have implemented a "Reverse - SBIRT" approach to communicate with controlled drug prescribers who appear on substance abusing patient's PMP profiles. The Screening in this reverse approach involves using PMP reports to screen for prescribers who are currently prescribing controlled drugs to high risk patients. The Brief Intervention consists of notifying these prescribers of their patients high risk status and the necessity of factoring this information into future prescribing decisions. The Referral to Treatment in this approach involves the possible referral of the prescriber for evaluation by his or her licensure board for remedial education in the prescribing of controlled drugs if the prescribing pattern appears intractable or egregious.

    Theodore V. Parran

    MD, FACP, FASAM

    Dr. Ted Parran is a 1978 graduate with honors in History from Kenyon College and a 1982 graduate from Case Western Reserve University School of Medicine.  He completed a residency in Internal Medicine at the Baltimore City Hospital of Johns Hopkins University School of Medicine. Following his residency, Dr. Parran was selected to be the Medical Chief Resident.  In 1987, he received the Outstanding Faculty Teacher Award from the Department of Medicine.  In 1988 he returned to Cleveland and CWRU School of Medicine.  

    Dr. Parran pursues several areas of special interest in medical education including Doctor – Patient Communication, Faculty Development, Continuing Medical Education, and Addiction Medicine.  
    In addition, Dr. Parran is board certified in Internal medicine and Addiction Medicine, and his group practice provides medical directorship services to several Substance Abuse treatment programs in northeast Ohio.  He is widely published and has been an invited speaker at national and international conferences for the past two and a half decades.  
    He established the Addiction Fellowship Program at CWRU School of Medicine in 1994, teaches on the Addiction Psychiatry Fellowship faculty and co-directs the current Addiction Medicine Fellowship Program at St. Vincent charity Hospital.  Dr. Parran is the co-director of the Foundations of Clinical Medicine Course, a course with topics which touch on the doctor patient relationship, health disparities, professionalism, cultural competence and health policy.  He is the medical director of the Program in Continuing Medical Education, and in 2007 was named as the Isabel and Carter Wang Professor and Chair in Medical Education, all at CWRU School of Medicine. 

  • Substance Withdrawal in Pregnancy: From Research to Practice to Public Health (2 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    Jim Walsh and Vania Rudolf will address challenges and practical considerations for OAT and summarize its benefits for maternal and neonatal outcomes when compared to medication assisted withdrawal management.

    Substance use in pregnancy is a major, often underdiagnosed health problem for women, regardless of age, race, ethnicity, and socioeconomic status, and has resulting high costs for individuals and society. Early identification and timely treatment improves maternal and neonatal outcomes. Current evidence supports opioid agonist therapy (OAT) as a safe, effective modality for pregnant and parenting women with opioid use disorder. However, due to barriers to accessing care, lack of provider skill, geographical patterns, and marked socio-economic disparities, only a minority receive OAT. In addition, punitive attitudes and health policies have the potential to lead to under-treatment and social marginalization. Providing clinical recommendations and developing safe guidelines to improve care for pregnant women with substance use disorders and their children is gaining in priority for programming, policy and research. The panel will discuss how to treat women with substance use disorders during pregnancy and provide practical approaches for evidence-based management of opioid and sedative use disorder. Perinatal, neonatal, public health and research perspectives will be condensed, with the aim to translate data into a practical clinical guide. Mishka Terplan will discuss treatment through a public health lens highlighting gaps between evidence-based practice and the actual landscape of care. Hendree Jones will provide research data on evidence-based practices for treating pregnant women with opioid use disorder (OUD). Tricia Wright will present a longitudinal perspective and clinical guide for managing pregnant and parenting women on OAT, including women with co-occurring alcohol and sedative use. Jim Walsh and Vania Rudolf will address challenges and practical considerations for OAT and summarize its benefits for maternal and neonatal outcomes when compared to medication assisted withdrawal management.

    Mishka Terplan

    MD, MPH, FACOG, FASAM

    Mishka Terplan is a physician boarded in both obstetrics and gynecology and addiction medicine. His clinical, research and advocacy work focuses on the intersection of reproductive health and addictions. He is currently Medical Director of Behavioral Health System Baltimore, the local behavioral health authority, adjunct faculty at University of Maryland Department Epidemiology and Public Health, and staff physician at Planned Parenthood Maryland. He has represented both the American Congress of Obstetricians and Gynecologists (ACOG) and the American Society of Addiction Medicine (ASAM) on federal taskforces and in testimony including before the House Energy and Commerce Subcommittee regarding H.R. 1462, the “Protecting Our Infants Act".

    Tricia Wright

    MD, MS, FACOG, FASAM

    Tricia Wright, MD MS is an assistant professor of Obstetrics, Gynecology and Women's Health at the University of Hawaii John A. Burns School of Medicine and founder, former medical director, and now Women's Health Liaison of the PATH Clinic, an outreach clinic of Waikiki Health Center, which provides prenatal, postpartum and family planning to women with a history of substance use disorders. She is board certified in both Ob/Gyn and Addiction Medicine and a Fellow of the American College of Obstetrics and Gynecology. She has been waivered to provide buprenorphine since 2009, and has treated both pregnant and non-pregnant women. She won funding approval in 2006 from the Hawaii legislature to start a perinatal clinic for women with substance use, the first in the state. The Path Clinic opened in 2007, and has seen over 400 pregnant women since that time. She completed her Masters Degree in Clinical Research from the University of Hawaii in 2009, her thesis paper studying the disparities of smoking and drug use rates during pregnancy of Native Hawaiian women. Her research interests include substance use disorders among pregnant women, including barriers to family planning, screening, brief intervention and referral to treatment (SBIRT), best practices for treatment, and the effects of methamphetamine, marijuana and tobacco on the placenta.

    Hendree Jones

    PhD

    Hendree Jones, PhD is a Professor in the Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina, Chapel Hill and Executive Director of Horizons, a comprehensive drug treatment program for pregnant and parenting women and their drug-exposed children. She is also an Adjunct Professor in the Department of Psychology, UNC, Chapel Hill and an Adjunct Professor in the Psychiatry and Behavioral Sciences and in the Department of Obstetrics and Gynecology, School of Medicine, Johns Hopkins University. 

    Dr. Jones is an internationally recognized expert in the development and examination of both behavioral and pharmacologic treatments for pregnant women and their children in risky life situations. Dr. Jones has received continuous funding from the United States National Institutes of Health since 1994 and has published over 185 publications, two books on treating substance use disorders (one for pregnant and parenting women and the other for a more general population of patients), numerous book and textbook chapters. She is a consultant for SAMHSA, the United Nations and the World Health Organization. 

    Dr. Jones leads or is involved in projects in Afghanistan, the South America, the Republic of Georgia, South Africa, and the United States which are focused on improving the lives of children, women and families.

    Jim Walsh

    MD

    Dr. Walsh attended medical school at SUNY Downstate and completed family medicine residency training at Montefiore in the Bronx in 1998.  He worked as a primary care provider at a Community Health Center for 7 years before completing fellowships in Addiction Medicine and High Risk Pregnancy Management. Since then he has worked at the Addiction Recovery Service at Swedish Medical Center in Seattle, becoming Medical Director of the Service in 2006.

    At Swedish we provide prenatal care and delivery services, as well as inpatient rehabilitation and opiate maintenance treatment for pregnant women with substance use problems.  We also offer inpatient medically managed withdrawal and addiction medicine outpatient services for patients who aren't pregnant.   We have been training physicians in addiction medicine since 2002.  Our fellowship program was accredited by ABAM in 2014.

    Vania Rudolf

    MD, MPH, FASAM

    Dr. Rudolf is board certified in addiction medicine and family medicine. She received her medical degree from Sofia Medical University and completed residency in family medicine with high risk obstetrics at Tacoma Family Medicine, UW Family Medicine Residency Network. She pursued further public health education at the University of WA and has completed fellowships in Integrative Medicine at University of AZ, Addiction Medicine at Swedish Medical Center, Seattle and most recently Advanced Obstetrics Fellowship under Maternal Fetal Medicine at Swedish Medical Center, Seattle, WA. Clinically she provides specialty inpatient and outpatient services to pregnant women with substance use disorders. Her ultimate professional goal is to positively impact the lives of patients with addiction, with emphasis on public health clinical outcomes and social justice.Her research efforts are dedicated to promotion of compassionate care, elimination of treatment barriers, diminishing stigmatization, and building innovative frameworks for both healthcare providers and patients.

  • Marijuana: From Bench to Policy (1.5 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    There are controversies regarding marijuana in the development of current public policy in the United States through legalization and/or decriminalization of medical marijuana and recreational marijuana throughout the nation, and worldwide as well. Informed addiction physicians are best qualified to opine, advise and advocate for improved public policy regarding marijuana use, access and promotion. This symposium will provide opinion survey data of ASAM and ISAM physicians. Overall perspectives from highly qualified scientists and professionals related to the impact of marijuana policies on individuals, families and communities in diverse cultural settings will be presented.

    https://www.surveymonkey.com/r... There are controversies regarding marijuana in the development of current public policy in the United States through legalization and/or decriminalization of medical marijuana and recreational marijuana throughout the nation and worldwide as well. Informed addiction physicians are best qualified to opine, advise and advocate for improved public policy regarding marijuana use, access and promotion. This symposium will provide opinion survey data of ASAM and ISAM physicians focusing on five critical areas: (i) potential adverse effects of marijuana use/abuse including data on the addictive potential, toxicity and gateway effect; (ii) the more specific effects of cannabis use on vulnerable populations including youth (i.e. adolescents and young adults), those individuals with mental illness, and those with abuse/addiction histories with alcohol or other drugs; (iii) potential therapeutic clinically appropriate indications for prescribed cannabinoids including crude marijuana and approved cannabinoid related medications; (iv) public policies defining legalization and/or decriminalization of medical marijuana and recreational marijuana; and finally (v) medical professional guidelines and/or position papers regarding the legalization and/or decriminalization of medical marijuana and recreational marijuana. A comparative analysis of models of regulated or unregulated legalization or decriminalization of medicinal or recreational marijuana will be included as the California model, the New York model, the Holland model, and the Colorado model. More current proposals for regulated access to marijuana including the Canadian will be described. Varying perspectives from highly qualified scientists and professionals related to the impact of marijuana policies on individuals, families and communities in diverse cultural settings will be discussed.

    Marc Galanter

    MD, DFASAM

    Marc Galanter, M.D., is a Professor of Psychiatry at NYU, Founding Director of the Division of Alcoholism and Drug Abuse, a Senior Editor of the Journal “Substance Abuse,” and co-editor of the American Psychiatric Association's “Textbook of Substance Abuse Treatment.” He has written four books, “Cults: Faith, Healing, and Coercion,” “Network Therapy for Alcohol and Drug Abuse,” “Spirituality and the Healthy Mind,” and "What is Alcoholics Anonymous?", and published over 200 peer-reviewed articles. His NIH and foundation-funded studies have addressed network therapy for substance abuse, pharmacologic treatment for addiction, the psychology of Twelve-Step recovery, and spirituality in healthcare.

    Dr. Galanter attended Albert Einstein College of Medicine where he did his residency in psychiatry. After that he was a Clinical Associate of the National Institute of Mental Health, then an NIH Career Teacher. He later served as President of the Association for Medical Education and Research in Substance Abuse (AMERSA, 1976-1977), the American Academy of Addiction Psychiatry (AAAP, 1991-1992), and the American Society of Addiction Medicine (ASAM, 1999-2001). Among his awards are the Gold Achievement Award for Innovation in Clinical Care, the Oskar Pfister Award for Spirituality, Religion and Psychiatry, and the Seymour Vestermark Award for Psychiatric Education, all from the American Psychiatric Association; the McGovern Award for Medical teaching from AMERSA; the Smithers Award for Research form ASAM; and New York State's Award for Psychiatric Research.

    Ben Cort

    MS

    Ben’s passion for recovery, prevention and harm reduction comes from his own struggle with substance abuse. Sober since 6/15/96, Ben has been a part of the recovery community in almost every way imaginable; from a recipient to a provider to a spokesperson Cort has a deep understanding of the issues and a personal motivation to see the harmful effects of drug and alcohol abuse minimized.In 2007 Ben left his position as a HR director inside of a Denver based S&P 500 firm to help start the Colorado based nonprofit, Phoenix Multisport (PM). As an original board member and then their first full time employee, Ben was instrumental in building this organization that has received frequent national recognition for their innovative approach to building sober communities around sport and healthy activities. Ben joined the drug policy conversation at the national level in 2012 after leaving PM to be a part of the “No on 64” Campaign. Following the passage of A64 he has been appointed to the Board of Directors of Project SAM (Smart Approaches to Marijuana) As well as NALGAP (the National Association of Lesbian, Gay, and Transgender Treatment Providers and their Allies). Ben’s passion about the intersection of recovery and public policy makes him frequent guest in the media.His first book, Stirring the Pot – A book about weed, published by HCI is due out in 2017. Ben resigned from his position with the University of Colorado Hospital inside of their chemical dependency treatment service line in January 2017 to focus on marijuana education and consulting inside of the substance use disorder treatment field. 

    Robert L. DuPont

    MD, DFASAM

    For more than 40 years, Robert L. DuPont, M.D. has been a leader in drug abuse prevention and treatment. He served as the first Director of the National Institute on Drug Abuse (1973-1978) and as the second White House Drug Chief (1973-1977). From 1968-1970 he was Director of Community Services for the District of Columbia Department of Corrections, heading parole and half-way house services. From 1970-1973, he served as Administrator of the District of Columbia Narcotics Treatment Administration. Following this distinguished public career, in 1978 Dr. DuPont became the founding president of the Institute for Behavior and Health, Inc., a non-profit organization that identifies and promotes new ideas to reduce illegal drug use. He has been Clinical Professor of Psychiatry at the Georgetown University School of Medicine since 1980. 

    A graduate of Emory University, Dr. DuPont received an M.D. degree in 1963 from the Harvard Medical School. He completed his psychiatric training at Harvard and the National Institutes of Health in Bethesda, Maryland. 

    Dr. DuPont is a Life Fellow of the American Society of Addiction Medicine. His activities in ASAM include chairing the forensic science committee from 1995 to 2004, and serving as Co-Chair of the two White Paper writing committees that produced The Role of the Physician in “Medical” Marijuana in 2010 and State-Level Proposals to Legalize Marijuana in 2012. He served as Chair of the writing committee that produced Drug Testing: A White Paper of the American Society of Addiction Medicine in 2013. He is also a Life Fellow of the American Psychiatric Association and was chairman of the Drug Dependence Section of the World Psychiatric Association from 1974 to 1979. In 1989 he became a founding member of the Medical Review Officer Committee of ASAM."

    Gregory C. Bunt

    MD, FASAM

    Dr. Gregory Bunt graduated from NYU School of Medicine in 1983, completed his residency in Psychiatry at the AECOM in 1987, and a Fellowship in Addiction Psychiatry at NYU (1989), and is currently as an Assistant Clinical Professor of Psychiatry at NYU. He is a diplomat of the American Board of Psychiatry and Neurology in Addiction Psychiatry. Dr. Bunt is currently the medical director of Daytop Village and consultant to Daytop International. Dr. Bunt also serves as the President of the New York Society of Addiction Medicine and the President-Elect of the International Society of Addiction Medicine as well. He has authored over a dozen publications, and speaks nationally and internationally on the subject of therapeutic communities.

    Jag Khalsa

    PhD, MS

    Dr. Jag Khalsa, with about 50 years of experience in drug research, serves as the Chief of the Medical Consequences Branch, National Institute on Drug Abuse, NIH, DHHS; is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others). Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He also serves on numerous Federal and NIH level committees including the HHS Viral Hepatitis Implementation Group (VHIG), National Commission on Digestive Diseases and its two sub-committees (Liver Research, Diabetes Research), Federal Task Force on TB, NIH Steering Committee on Centers for AIDS Research. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, Society of Neuro-Immune-Pharmacology (SNIP), Life Time Achievement Awards from SNIP and International Conference on Molecular Medicine (India) and MIT, India; a commendation from the US Congress, Awards of Merit from the International Society of Addiction Medicine (ISAM), the President of the American Society of Addiction Medicine (ASAM), and a Certificate of Appreciation from the Office of Assistant Secretary for Health (Drs. Howard Koh and Ron Valdiserri), DHHS. He has a Ph.D. in neuro-psycho-pharmacology, a Master's degree in herbal pharmacology/medicine, post-doctoral training in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International. E-mail: jk98p@nih.gov

  • Overview of Addiction Medicine, 2016-2017: A Rapid Review (1.5 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    This is a rapid-fire, journal club presentation reviewing high impact publications in the field from 2016-2017, organized by the core chapters of the ASAM Principles of Addiction Medicine textbook.

    This session is an annual review of the highest impact peer-reviewed articles from our field for 2016-2017. This symposium organizes brief journal club-type presentations using the chapter outline of ASAM's Principles of Addiction Medicine text: neurobiology, epidemiology, pharmacology, intoxication and withdrawal syndromes, screening and diagnosis, mutual help, harm reduction, criminal justice, dual diagnoses, and pharmacologic and behavioral interventions. The goal of this symposium is to provide the learner with a concise, structured, and evidence-based summary of the most recent scientific evidence. All of the core Principles chapters are covered, using the highest rated (impact, reach) articles on these topics. Articles are selected by relevance to the topic outline, publication metrics (journal impact factor, most downloaded, Altmetric rankings), and expert opinion. Example articles include the 2016 CDC chronic pain and opioid guidelines, a randomized controlled trial of buprenorphine + XR-naltrexone for cocaine use, the impact of the DEA rescheduling of hydrocodone products, and epidemiologic findings in a national sample of associations between cannabis use and downstream mood and other substance use disorders.

    Sarah Wakeman

    MD, FASAM

    Sarah E. Wakeman, MD is the Medical Director for the Mass General Hospital Substance Use Disorder Initiative, program director of the Mass General Addiction Medicine fellowship, and an Assistant Professor of Medicine at Harvard Medical School. She is also the Medical Director of the Mass General Hospital Addiction Consult Team, co-chair of the Mass General Opioid Task Force, and clinical lead of the Partners Healthcare Substance Use Disorder Initiative. She is the Medical Director of RIZE Massachusetts, a state-wide, private sector initiative created to build a $50 million fund to implement and evaluate innovative interventions to address the opioid overdose crisis. She received her A.B. from Brown University and her M.D. from Brown Medical School. She completed residency training in internal medicine and served as Chief Medical Resident at Mass General Hospital. She is a diplomate and fellow of the American Board of Addiction Medicine. She is chair of the policy committee for the Massachusetts Society of Addiction Medicine. She served on Massachusetts' Governor Baker’s Opioid Addiction Working Group. Nationally, she is chair of the American Society of Addiction Medicine Drug Court Task Force and serves on their ethics committee.Clinically she provides specialty addiction and general medical care in the inpatient and outpatient setting at Mass General Hospital and the Mass General Charlestown Health Center. Her research interests include evaluating models for integrated substance use disorder treatment in medical settings, recovery coaching, physician attitudes and practice related to substance use disorder, and screening for substance use in primary care.

    Joshua D. Lee

    MD, MSc, FASAM

    Joshua D. Lee MD, MSc is an Associate Professor in the Departments of Population Health and Medicine at the NYU School of Medicine. He is board-certified in Internal Medicine and Addiction Medicine and is a physician at Bellevue Hospital Center, NYU Langone Medical Center, and in the NYC jails. He directs the NYU ABAM Fellowship in Addiction Medicine. His research focuses on novel and medication treatments for addiction among criminal justice and primary care populations.

  • Engaging Healthcare Practitioners to Address the Opioid Crisis (1.5 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    This session will review: Survey data of NPs interest in treating OUD and obtaining a waiver to prescribe MATs; Potential barriers for NPs related to prescribing MATs and Current status of number of NPs that have registered for the required 24 hours of education for waiver application.

    Despite substantial efforts to encourage adoption of evidence-based practices, the use of medications to treat substance use disorders is still low in both primary care and specialty addiction treatment settings. In this presentation the status of efforts to implement buprenorphine prescribing in primary care and other settings will be described. Barriers to treatment for opioid use disorders and potential strategies to address them such as collaborative care models will be discussed. Successful strategies and lessons learned from efforts to encourage the provision of buprenorphine in specialty and general medical settings will be identified in order to inform future efforts to expand access to medication for opioid use disorder. The Massachusetts Collaborative Care Model for the delivery of opioid agonist therapy with buprenorphine, in which nurses working with physicians play a central role in the evaluation and monitoring of patients, holds promise for the effective expansion of treatment for opioid use disorders. The Massachusetts Bureau of Substance Abuse Services (BSAS) initiative to implement the office-based opioid treatment with buprenorphine (OBOT-B) collaborative care model in fourteen community health centers (CHCs) will be described. With the passage of the Comprehensive Addiction and Recovery Act of 2016 (CARA), significant changes to federal policies will ultimately increase states' capacity to provide medication-assisted treatment. Representatives from the American Association of Nurse Practitioners (AANP), the American Academy of Physician Assistants (AAPA), and the American Society of Addiction Medicine (ASAM) Medical Education Council will describe stakeholders' interest in providing treatment for substance use disorders and identify needs of their constituencies. Each speaker will provide recommendations regarding the messaging needed to address stigma and to engage healthcare professionals. Speakers will also identify potential pitfalls or barriers to consider in efforts to encourage healthcare practitioners to identify and treat substance use disorders. After brief didactic presentations, a panel discussion with addiction medicine experts and representatives from nursing, NP, and PA communities will be held. Through interactive discussion speakers will address questions most relevant to attendees and discuss factors influencing the engagement of healthcare practitioners in local settings to increase access to appropriate, evidence-based treatments for opioid use disorder across the country.

    Kristen Huntley

    PhD

    Kristen Huntley, Ph.D., is a Health Scientist Administrator at the National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Center for Clinical Trials Network (CCTN) where she oversees research studying the effectiveness and implementation of interventions for the treatment of substance use disorders in multi-site, nationwide studies that enroll large samples of diverse participants in general medical settings and community-based treatment programs. Dr. Huntley also manages activities conducted through NIDA’s Blending Initiative. This initiative supports collaboration between clinicians, scientists, and experienced educators to facilitate the adoption of evidence-based practices in front-line clinical settings. During her tenure at NIH Dr. Huntley has served as a Scientific Review Officer at NIDA and as a Program Director at the National Center for Complementary and Integrative Health (NCCIH) where she administered a portfolio of pain management research grants and led efforts to build collaborations with other federal agencies to encourage research on the use of integrative models of care in military and veteran populations. Prior to working at NIH, Dr. Huntley was on the faculty at Case Western Reserve University School of Medicine, a project director at a research and consulting firm, and has worked in a variety of healthcare settings. Dr. Huntley has a Ph.D. in clinical psychology and has over 20 years of experience in academic, research, and clinical settings.

    Jeffrey Samet

    MD, MA, MPH

    Dr. Samet is a graduate of Brandeis University and Baylor College of Medicine. He trained in Internal Medicine at Boston City Hospital, Boston University School of Medicine (BUSM), and in a research fellowship at the Massachusetts General Hospital. He has been a primary care physician in Boston since 1983. Dr. Samet is a Professor of Medicine at Boston University School of Medicine and Professor of Community Health Sciences at the Boston University School of Public Health. In 2002, he became the Chief of General Internal Medicine at BUSM/Boston Medical Center and Vice Chair for Public Health in the Department of Medicine. Dr. Samet has a longstanding commitment to educating physicians about substance use disorders. From 1995-2012 he served as Medical Director of Substance Abuse Prevention and Treatment Services for the Boston Public Health Commission. He was President of the Association of Medical Education and Research in Substance Abuse (1999- 2001), co-chair of the Substance Abuse Task Force of the Society of General Internal Medicine (1992-2002), and a member of the Institute of Medicine Committee on Addressing the Quality Chasm in Mental Health and Addictive Disorders. Dr. Samet chaired the ASAM Medical-Scientific Annual Conference Program Committee 2004-2010 and 2012-2013 he served as President of the American Board of Addiction Medicine (ABAM) and the ABAM Foundation.

    Colleen LaBelle

    BSN, RN-BC, CARN

    Colleen LaBelle has certifications in addiction nursing and HIV with over 20 years of clinical experience in HIV and addiction, and co-authored a publication in the Journal of General Internal Medicine, “Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-based Setting." She was instrumental in the start up of the OBOT Program in the BMC Primary Care Clinic, which manages over 450 active patients with buprenorphine. This program provides buprenorphine treatment for patients in primary care, homeless, HIV, Family Medicine, OB, and support to the affiliated community health centers. She is the program director of the STATE OBOT B (State Technical Assistance, Treatment Expansion of Buprenorphine) working with 14 community health centers implementing a nurse care manager model for the expansion of buprenorphine. Since 2003, Ms. LaBelle has served as Faculty for the buprenorphine certification course of the American Society of Addiction Medicine. She frequently gives presentations on buprenorphine and provides consultation and technical assistance on- and offsite and by telephone. She oversees the MDPH buprenorphine list-serve and provides liaison for MDPH supported buprenorphine training, education and start-up in Massachusetts. She speaks on a local and national level, and has been a part of the SAMHSA Summit on Buprenorphine. Ms. LaBelle has served as a member of the Scientific Study (Study Section) Review Committee for the National Institute on Drug Abuse. Since 2004, she has served on the National Advisory Committee on Buprenorphine for the Health Resources and Services Administration and participated in professional editing of TAP 30 Technical Assistance Publication for Nurses with SAMHSA, 2009. Co-author : Five Year Experience with Collaborative Care of Opioid Addicted Patients using Buprenorphine in Primary Care, published Archives of Internal Medicine. In May 2011 she was the recipient of Individual Leadership Award, for Innovation In Health Care from MA Bureau of Substance Abuse Services as well as a NIATX award recipient 2011 Innovations in Behavioral Health Services award for Process Improvements. She is a board member of the Addiction Nurses Certification Board, and recently started a MA Chapter for addiction nurses.

    Andrew Saxon

    MD, FASAM

    Andrew J. Saxon, M.D. Professor, Department of Psychiatry and Behavioral Sciences, University of Washington Director, Center of Excellence in Substance Abuse Treatment and Education, VA Puget Sound Health Care System Director, Addiction Psychiatry Residency Program, University of Washington Preceding his entry into psychiatry, Dr. Saxon completed an internal medicine internship and worked for 4 years as an emergency room physician. Subsequent to his general psychiatry residency at the University of Washington, Dr. Saxon has more than a quarter century of experience as a clinical and research addiction psychiatrist. Dr. Saxon is board certified with added qualifications in addiction psychiatry by the American Board of Psychiatry and Neurology. Dr. Saxon sits on the editorial boards of the journals, Drug and Alcohol Dependence and General Hospital Psychiatry. Dr. Saxon's current research work is supported by the VA, the Department of Defense, and the National Institute on Drug Abuse and involves pharmacotherapies and psychotherapies for alcohol, cocaine, tobacco, and opioid use disorders as well work in co-occurrence of substance use disorders and posttraumatic stress disorder and on reducing homelessness.

    Marie-Michele Leger

    MPH, PA-C

    Ms. Léger a PA for 33 years is director, clinical education at AAPA.  She obtained a  Bachelor’s of Science, Physician Assistant Program, George Washington University (GWU), Washington DC in 1983 and completed her Master in Public Health, (International Health, Concentration: Health Promotion/Disease Prevention), from GWU in 1996.  
    She monitors, advises AAPA’s leadership on issues in clinical medicine, public health, coordinates activities that relates to continuous professional development, translate best available evidence which leads to PA practice improvement.   Ms.  Léger is the AAPA’s liaison to the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP).  She has published extensively; written editorials on raising the awareness of emergency preparedness and raising the rate of adult immunization.  Ms. Léger has given presentations in the United States and internationally addressing the PA profession, disparity in healthcare, immunization, and other infectious disease topics.  Ms. Léger retains a faculty appointment at the George Washington University School of Medicine and Health Sciences and at the Shenandoah Physician Assistant Program.

    Anne Norman

    DNP, APRN, FNP-C, FAANP

    Dr. Anne Norman is a Family Nurse Practitioner (FNP) and the Vice President of Education and Accreditation at the American Association of Nurse Practitioners (AANP).  She received her Master of Science in Nursing at the University of Alabama at Huntsville in 1994 and her Doctor of Nursing Practice at the University of Alabama at Birmingham in 2010.  Dr. Norman has practiced in primary care and held leadership positions in various settings including: a multiple disciplinary medical school health center, rural health, college health, retail health and workplace/occupational health.  At AANP, she serves as the primary organizational resource on continuing education (CE) and education-related standards, recommendations, and requirements.  Her responsibilities include directing the grant, education, and accreditation activities of the association by overseeing and guiding the planning, development, and implementation of educational activities and programs to meet strategic goals.

    Daniel P. Alford

    MD, MPH, FACP, DFASAM

    Dr. Daniel P. Alford is an Associate Professor of Medicine, Assistant Dean of CME and Director of the Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program at Boston University School of Medicine. He is a diplomate in Addiction Medicine by the American Board of Addiction Medicine (ABAM).

    He is director of the Clinical Addiction Research and Education Unit medical director of the Office-Based Opioid Treatment (OBOT) program and of the Massachusetts Screening, Brief Intervention, Referral to Treatment Training and Technical Assistance (MASBIRT TTA) program and former program director for the Addiction Medicine Fellowship program at Boston Medical Center (BMC). Since 2001 he has served as the course director of the Chief Resident Immersion Training (CRIT) Program in Addiction Medicine: Improving Clinical and Teaching Skills for Generalists funded by NIDA. He is president of the Association for Medical Education and Research in Substance Abuse (AMERSA). In 2011, he was recognized as a Champion of Change by the White House. In 2014 he received the Health Education Award from the American Medical Association.

  • Interventional Pain Management: A Pain Control Strategy for the Patient in Treatment (1.5 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    The presentation will include vignettes of treatment options for problems that are commonly seen in both the pain management office, and the addiction treatment setting. A brief overview of the type of available procedures, and their risks and options will be discussed. We will then allow time for questions. Drs. Hansen and Silverman are both active and Board members of the American Society of Interventional Pain Physicians, which is a group of physicians and extended care providers that train and provide resources to treat our patients in pain. Their experience in pain medicine and addiction medicine allow them to present a perspective that is unique to the complex patient in treatment and pain.

    The patient in treatment presents in many complex forms, often with a complaint of pain. The pain may have been the origin of the addiction, or might be a process that shares a relationship to the purpose driven seeking of controlled substances, particularly opioids. Pain and addiction are often seen together, and an item of significant risk in both the pain management population, and the substance abuse arena. The overlap of symptoms is common. The practitioner often searches for alternative care strategies, to minimize opioid load, and improve function and quality of life. It is the purpose of this presentation to demonstrate a very powerful therapeutic pathway, with emphasis on pain control, without escalating controlled substances. Many examples of success have eliminated controlled substances and reduced pain. These interventional techniques that are performed are both diagnostic and therapeutic, and assist in an overall strategy of independence from opioid management of pain. Discussed will be spinal procedures, musculoskeletal procedures, and vignettes apply these therapies to a practical world. Interventional procedures are often very cost effective, that enhance positive benchmarks in a timely fashion. Interventional pain medicine is the application of target specific medication therapy to a pain generator. Interventional pain medicine also includes advanced technology such as spinal cord stimulation, and radiofrequency ablation that addresses pain refractory to common therapeutic approaches. An interventional pain physician might come from neurology, anesthesiology, or physical medicine and rehab, as a primary specialty, with added training and credentials to demonstrate proficiency. In proper hands these procedures are safe, cost effective, and afford very specific populations control of one of the most common complaints in American medicine, pain. As new technologies emerge, an exciting emergence of cutting edge thought, even rejuvenative medicine can return an individual to an active and functioning vital member of society. The fragile pain population of those in treatment for addiction can ill afford the setbacks of those suffering from pain with no hope. These techniques and the promise of new advances in development, lend to an important academic discussion that is timely for those who treat addiction.

    Sanford M. Silverman

    MD

    Sanford M. Silverman, MD, is in private practice; Institute of Pain Management, Pompano Beach, Florida. He is board certified in anesthesiology, with added qualifications in Pain Management from the American Board of Anesthesiology and a Diplomate in Pain Medicine from the American Board of Pain Medicine.  He is also a Diplomate in Addiction Medicine from the American Board of Addiction Medicine.  His practice consists of interventional and medical treatment of chronic pain, the treatment of various addictive disorders, and currently has an interest in treating complex chronic pain, addiction, and hyperalgesia.

    After receiving his bachelor and master degrees in Chemical Engineering from Tufts University in Medford, Massachusetts, Dr. Silverman earned his medical degree from New York Medical College. He then entered active duty military service with the US Army and completed a transitional internship at Letterman Army Medical Center in San Francisco, California. He then completed a residency in anesthesiology at Brooke Army Medical Center in San Antonio, Texas.  
    After completing his training, he served as Major, US Army and Chief of the Anesthesia and Operative Service at William Beaumont Army Medical Center in El Paso, Texas where he also was also the director of the pain clinic. 
    Dr. Silverman is the director of the Controlled Substance Management course, for the American Society of Interventional Physicians which is a core requirement for board certification in Interventional Pain Medicine.  In 2016 he co-authored a text book titled: Controlled Substance Management in Chronic Pain; A Balanced Approach. 
    Dr. Silverman is also an Affiliate Assistant Professor of Clinical Biomedical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University Charles E. Schmidt College of Medicine, Florida Atlantic University,  Boca Raton, FL., 
     Dr. Silverman served on the stakeholder committee of the CDC Opioid Guidelines, representing ASIPP. 

    Hans C. Hansen

    MD

    Hans C. Hansen, MD 

    President-Elect, ASIPP 
    Executive Director, NCSIPP 
    Medical Director, 
    The Pain Relief Centers, PA  
    Conover, North Carolina 

    Hans C. Hansen, M.D. was raised in Denver, Colorado, where he received his Doctorate in Medicine from the University of Colorado Health Sciences Center.  He trained and completed his residency in anesthesiology and a subspecialty year in chronic pain management at Yale University School of Medicine.  Dr. Hansen is board certified and re-certified by the American Board of Pain Medicine, completed testing for the World Institute of Pain, assisted in administration of the second FIPP exam, and is credentialed with the American Board of Interventional Pain Physicians (ABIPP).  He is on the Board of Directors, a past president, and current president-elect of American Society of Interventional Pain Physicians (ASIPP). He is board certified in Addiction Medicine. Dr. Hansen’s practice is located in Central Piedmont North Carolina.